Reed - Lane Inc

Reed - Lane Inc is a privately held pharmaceutical contract packaging company headquartered in Wayne, New Jersey. Established in 1959, Reed - Lane specializes in providing innovative packaging solutions for prescription (Rx), over-the-counter (OTC), and generic pharmaceutical products. Their services encompass blister packaging, bottling, pouching, and convenience vial filling, catering to a diverse clientele in the pharmaceutical industry.

The company operates from a 132,000-square-foot facility in Wayne, NJ, featuring over 25 dedicated production suites. These facilities are equipped with individual air handling and HEPA filtration systems, temperature-controlled storage for bulk and finished goods, and stringent environmental and security monitoring, including over 150 high-definition CCTV cameras. Reed - Lane is licensed by the U.S. Drug Enforcement Administration (DEA) to package controlled substances classified as Schedule III–V drugs.

Reed - Lane's distribution network is primarily centered within the United States, with its main operations based in Wayne, New Jersey. The company's 132,000-square-foot facility serves as the hub for its packaging and distribution activities. While specific details about additional warehouse locations or logistics capabilities beyond this facility are not publicly disclosed, Reed - Lane's extensive warehousing space and fully validated Enterprise Resource Planning (ERP) system suggest a robust infrastructure capable of managing significant distribution needs.

Reed - Lane Inc functions as a contract packaging service provider within the pharmaceutical supply chain. Unlike wholesalers or distributors, Reed - Lane specializes in the packaging of pharmaceutical products, including both prescription and over-the-counter medications. Their role is to prepare and package these products for distribution, ensuring compliance with industry standards and regulations. This positions Reed - Lane as a critical intermediary between pharmaceutical manufacturers and the end-users of these products.

Reed - Lane Inc's sourcing strategy exhibits a high degree of concentration, with a significant portion of their imported pharmaceutical products originating from India. Between 2022 and 2026, Reed - Lane imported finished pharmaceutical formulations valued at $1.1 million from India, encompassing 35 shipments and 70 unique formulations. The top four products imported include Guaifenesin ($522K), Dextromethorphan ($228K), Ephedrine ($200K), and Pseudoephedrine ($200K), all within the respiratory and OTC therapeutic category. This concentration indicates a strategic focus on specific products and suppliers.

The primary supplier, DR.REDDY'S LABORATORIES LIMITED, accounted for 78.5% of the total import value, followed by DR REDDYS LABORATORIES LIMITED with 20.5%, and GLAND PHARMA LIMITED with 1.0%. This heavy reliance on a limited number of suppliers may pose risks related to supply chain disruptions, pricing volatility, and dependency on supplier performance. However, it also suggests a strategic choice to maintain strong, focused relationships with key suppliers to ensure product quality and consistency.

Reed - Lane Inc's supply chain resilience is closely tied to its sourcing concentration from Indian suppliers. The company's reliance on a few key suppliers, particularly DR.REDDY'S LABORATORIES LIMITED, indicates a deep integration with these partners. While this can lead to streamlined operations and potential cost benefits, it also exposes Reed - Lane to risks associated with supply chain disruptions, such as production delays, regulatory changes, or geopolitical issues affecting India. The limited number of suppliers may also impact the company's ability to diversify its supply chain in response to market changes or disruptions.

Reed - Lane Inc's concentrated sourcing strategy positions the company to leverage strong relationships with key Indian suppliers, potentially securing favorable terms and ensuring consistent product quality. However, this approach also exposes Reed - Lane to risks associated with supply chain disruptions, pricing volatility, and dependency on supplier performance. For Indian exporters, understanding Reed - Lane's sourcing patterns presents an opportunity to strengthen existing partnerships and explore avenues for diversification within Reed - Lane's product portfolio. By offering complementary products or services, Indian exporters can enhance their value proposition and potentially increase their share in Reed - Lane's supply chain.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all drugs entering the U.S. market meet standards for quality, safety, and effectiveness. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, including requirements for drug registration, labeling, and manufacturing practices. The FDA's Regulatory Procedures Manual and Investigations Operations Manual outline the procedures for the importation and examination of drugs, including the authority to refuse admission to products that do not comply with FDA regulations.

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products comply with FDA regulations, including those related to Good Manufacturing Practices (GMP). The FDA recognizes GMP certifications from various international standards, such as EU GMP, WHO GMP, and PIC/S, provided they meet FDA criteria. Importers must verify that their foreign suppliers hold valid GMP certifications and that their manufacturing processes align with FDA standards. Additionally, importers must obtain wholesale distribution authorization and ensure that their products are properly labeled and registered with the FDA.

Imported pharmaceutical products must adhere to FDA requirements for quality and labeling. This includes compliance with batch testing and stability requirements to ensure product safety and efficacy. Labeling must meet FDA standards, including accurate and truthful information, appropriate language requirements, and adherence to serialization mandates for tracking and tracing products through the supply chain. The FDA reviews drug labeling at the time of import to verify compliance with regulations, and may refuse entry to products that are misbranded or do not meet labeling requirements.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These include updates to the Section 804 Importation Program, which allows for the importation of certain prescription drugs from Canada, and revisions to the FDA's Import Procedures Manual to enhance the efficiency and effectiveness of import operations. Additionally, the FDA has increased inspections and enforcement actions to ensure compliance with the Drug Supply Chain Security Act (DSCSA), impacting the importation of pharmaceutical products. These changes aim to strengthen the integrity of the pharmaceutical supply chain and ensure the safety and efficacy of imported drugs.

Reed - Lane Inc's focus on importing finished pharmaceutical formulations from India, particularly in the respiratory and OTC therapeutic categories, aligns with market demand for these products. The top four imported products—Guaifenesin, Dextromethorphan, Ephedrine, and Pseudoephedrine—are commonly used in over-the-counter cough and cold medications, indicating a strategic emphasis on high-demand consumer health products. This product strategy allows Reed - Lane to cater to a significant segment of the U.S. pharmaceutical market, addressing consumer needs for effective and accessible respiratory treatments.

Reed - Lane Inc's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on specific products within the respiratory and OTC therapeutic categories. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. By concentrating on a select range of products, Reed - Lane can maintain quality control and streamline its supply chain operations. India's role as a major supplier of generic pharmaceuticals to the U.S. market positions it as a key partner in Reed - Lane's procurement strategy.

Based on its product mix, Reed - Lane Inc serves the U.S. over-the-counter pharmaceutical market, focusing on respiratory treatments. By importing and packaging popular OTC medications, Reed - Lane positions itself as a contract packager that facilitates the availability of these products to consumers through various distribution channels, including retail pharmacies and online platforms. This market positioning enables Reed - Lane to meet consumer demand for accessible and effective health solutions.

There is a realistic opportunity for new Indian suppliers to engage with Reed - Lane Inc, particularly in the respiratory and OTC therapeutic categories. Reed - Lane's concentrated sourcing strategy suggests potential for diversification within its product portfolio. Indian exporters can explore opportunities to supply additional formulations or variations of existing products to meet evolving market demands. By understanding Reed - Lane's product focus and quality standards, Indian suppliers can tailor their offerings to align with Reed - Lane's requirements, potentially increasing their presence in the U.S